-
1
-
-
79751531393
-
Heart disease and stroke statistics - 2011 update: A report from the American Heart Association
-
21160056 10.1161/CIR.0b013e3182009701
-
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-209.
-
(2011)
Circulation
, vol.123
, Issue.4
-
-
Roger, V.L.1
Go, A.S.2
Lloyd-Jones, D.M.3
Adams, R.J.4
Berry, J.D.5
Brown, T.M.6
-
2
-
-
0036522084
-
The problem of chronic refractory angina; Report from the ESC Joint Study Group on the Treatment of Refractory Angina
-
11846493 10.1053/euhj.2001.2706 1:STN:280:DC%2BD387hsVCksw%3D%3D
-
Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002;23(5):355-70.
-
(2002)
Eur Heart J
, vol.23
, Issue.5
, pp. 355-370
-
-
Mannheimer, C.1
Camici, P.2
Chester, M.R.3
Collins, A.4
Dejongste, M.5
Eliasson, T.6
-
3
-
-
34247113737
-
Optimal medical therapy with or without PCI for stable coronary disease
-
17387127 10.1056/NEJMoa070829 1:CAS:528:DC%2BD2sXkt1Sjsbc%3D
-
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16.
-
(2007)
N Engl J Med
, vol.356
, Issue.15
, pp. 1503-1516
-
-
Boden, W.E.1
O'Rourke, R.A.2
Teo, K.K.3
Hartigan, P.M.4
Maron, D.J.5
Kostuk, W.J.6
-
4
-
-
83655167300
-
Stable angina pectoris: Antianginal therapies and future directions
-
Chaitman BR, Laddu AA. Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol. 2011;9(1):40-52.
-
(2011)
Nat Rev Cardiol.
, vol.9
, Issue.1
, pp. 40-52
-
-
Chaitman, B.R.1
Laddu, A.A.2
-
5
-
-
33750992379
-
-
Accessed 15 May 2012
-
Prescribing Information. http://www.ranexa.com/global/Prescribing- Information.aspx. Accessed 15 May 2012.
-
Prescribing Information
-
-
-
6
-
-
0008348082
-
-
European Medicines Agency Accessed 20 Aug 2012
-
European Medicines Agency. European public assessment report for Ranexa. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000805/WC500045940.pdf. Accessed 20 Aug 2012.
-
European Public Assessment Report for Ranexa
-
-
-
7
-
-
0021256845
-
Slow inactivation of a tetrodotoxin-sensitive current in canine cardiac Purkinje fibers
-
6324914 10.1016/S0006-3495(84)84187-9 1:CAS:528:DyaL2cXhslagsL4%3D
-
Gintant GA, Datyner NB, Cohen IS. Slow inactivation of a tetrodotoxin-sensitive current in canine cardiac Purkinje fibers. Biophys J. 1984;45(3):509-12.
-
(1984)
Biophys J
, vol.45
, Issue.3
, pp. 509-512
-
-
Gintant, G.A.1
Datyner, N.B.2
Cohen, I.S.3
-
8
-
-
0021824529
-
Slow currents through single sodium channels of the adult rat heart
-
2411848 10.1085/jgp.86.1.89 1:STN:280:DyaL2M3ptFKgug%3D%3D
-
Patlak JB, Ortiz M. Slow currents through single sodium channels of the adult rat heart. J Gen Physiol. 1985;86(1):89-104.
-
(1985)
J Gen Physiol
, vol.86
, Issue.1
, pp. 89-104
-
-
Patlak, J.B.1
Ortiz, M.2
-
9
-
-
0024503561
-
Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes
-
2536304 10.1161/01.RES.64.2.389 1:CAS:528:DyaL1MXhtFansrY%3D
-
Kiyosue T, Arita M. Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res. 1989;64(2):389-97.
-
(1989)
Circ Res
, vol.64
, Issue.2
, pp. 389-397
-
-
Kiyosue, T.1
Arita, M.2
-
10
-
-
0026781658
-
Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes
-
1422582 10.1111/j.1476-5381.1992.tb12743.x 1:CAS:528:DyaK38Xmt1KjsL4%3D
-
Ju YK, Saint DA, Gage PW. Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes. Br J Pharmacol. 1992;107(2):311-6.
-
(1992)
Br J Pharmacol
, vol.107
, Issue.2
, pp. 311-316
-
-
Ju, Y.K.1
Saint, D.A.2
Gage, P.W.3
-
11
-
-
0029952835
-
Hypoxia increases persistent sodium current in rat ventricular myocytes
-
Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol. 1996;497(Pt 2):337-47.
-
(1996)
J Physiol.
, vol.497
, Issue.PART 2
, pp. 337-347
-
-
Ju, Y.K.1
Saint, D.A.2
Gage, P.W.3
-
12
-
-
33745392178
-
Late sodium current in the pathophysiology of cardiovascular disease: Consequences of sodium-calcium overload
-
Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92 Suppl 4:iv1-5.
-
(2006)
Heart.
, vol.92
, Issue.SUPPL. 4
-
-
Noble, D.1
Noble, P.J.2
-
13
-
-
4444383632
-
Calcium overload and cardiac function
-
Vassalle M, Lin CI. Calcium overload and cardiac function. J Biomed Sci. 2004;11(5):542-65.
-
(2004)
J Biomed Sci.
, vol.11
, Issue.5
, pp. 542-565
-
-
Vassalle, M.1
Lin, C.I.2
-
14
-
-
85047676504
-
Inhibition of sodium and calcium overload pathology in the myocardium: A new cytoprotective principle
-
Ver Donck L, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc Res. 1993;27(3):349-57.
-
(1993)
Cardiovasc Res.
, vol.27
, Issue.3
, pp. 349-357
-
-
Ver Donck, L.1
Borgers, M.2
Verdonck, F.3
-
15
-
-
0038434117
-
Calcium and cardiac arrhythmias: DADs, EADs, and alternans
-
12892319 10.1080/713609356 1:CAS:528:DC%2BD3sXmtVWhs7k%3D
-
Clusin WT. Calcium and cardiac arrhythmias: DADs, EADs, and alternans. Crit Rev Clin Lab Sci. 2003;40(3):337-75.
-
(2003)
Crit Rev Clin Lab Sci
, vol.40
, Issue.3
, pp. 337-375
-
-
Clusin, W.T.1
-
16
-
-
33745368556
-
Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine
-
Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 Suppl 4:iv6-14.
-
(2006)
Heart.
, vol.92
, Issue.SUPPL. 4
-
-
Belardinelli, L.1
Shryock, J.C.2
Fraser, H.3
-
17
-
-
4344577023
-
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties
-
15302796 10.1161/01.CIR.0000139333.83620.5D 1:CAS:528: DC%2BD2cXms1Ogt7Y%3D
-
Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904-10.
-
(2004)
Circulation
, vol.110
, Issue.8
, pp. 904-910
-
-
Antzelevitch, C.1
Belardinelli, L.2
Zygmunt, A.C.3
Burashnikov, A.4
Di Diego, J.M.5
Fish, J.M.6
-
18
-
-
34748873780
-
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine
-
17785620 10.1161/CIRCULATIONAHA.107.704890 1:CAS:528:DC%2BD2sXhtVKiu7rE
-
Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116(13):1449-57.
-
(2007)
Circulation
, vol.116
, Issue.13
, pp. 1449-1457
-
-
Burashnikov, A.1
Di Diego, J.M.2
Zygmunt, A.C.3
Belardinelli, L.4
Antzelevitch, C.5
-
19
-
-
0035194585
-
Electrical heterogeneity within the ventricular wall
-
11770069 10.1007/s003950170002 1:STN:280:DC%2BD38%2FktlSruw%3D%3D
-
Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall. Basic Res Cardiol. 2001;96(6):517-27.
-
(2001)
Basic Res Cardiol
, vol.96
, Issue.6
, pp. 517-527
-
-
Antzelevitch, C.1
Fish, J.2
-
20
-
-
33646386662
-
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: Evidence for site of action
-
16520744 10.1038/sj.bjp.0706709 1:CAS:528:DC%2BD28XjvF2lt74%3D
-
Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148(1):16-24.
-
(2006)
Br J Pharmacol
, vol.148
, Issue.1
, pp. 16-24
-
-
Fredj, S.1
Sampson, K.J.2
Liu, H.3
Kass, R.S.4
-
21
-
-
33745251122
-
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction
-
16565163 10.1124/jpet.106.101832 1:CAS:528:DC%2BD28XmsFymtr0%3D
-
Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318(1):214-22.
-
(2006)
J Pharmacol Exp Ther
, vol.318
, Issue.1
, pp. 214-222
-
-
Song, Y.1
Shryock, J.C.2
Wagner, S.3
Maier, L.S.4
Belardinelli, L.5
-
22
-
-
33751214195
-
Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts
-
17027025 10.1016/j.yjmcc.2006.08.012 1:CAS:528:DC%2BD2sXisFaquw%3D%3D
-
Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41(6):1031-8.
-
(2006)
J Mol Cell Cardiol
, vol.41
, Issue.6
, pp. 1031-1038
-
-
Fraser, H.1
Belardinelli, L.2
Wang, L.3
Light, P.E.4
McVeigh, J.J.5
Clanachan, A.S.6
-
23
-
-
70350776813
-
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images
-
19909934 10.1016/j.jcmg.2009.09.006
-
Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009;2(11):1301-9.
-
(2009)
JACC Cardiovasc Imaging
, vol.2
, Issue.11
, pp. 1301-1309
-
-
Venkataraman, R.1
Belardinelli, L.2
Blackburn, B.3
Heo, J.4
Iskandrian, A.E.5
-
24
-
-
79960406156
-
The effect of ranolazine on the vasodilator-induced myocardial perfusion abnormality
-
21432000 10.1007/s12350-011-9364-1
-
Venkataraman R, Aljaroudi W, Belardinelli L, Heo J, Iskandrian AE. The effect of ranolazine on the vasodilator-induced myocardial perfusion abnormality. J Nucl Cardiol. 2011;18(3):456-62.
-
(2011)
J Nucl Cardiol
, vol.18
, Issue.3
, pp. 456-462
-
-
Venkataraman, R.1
Aljaroudi, W.2
Belardinelli, L.3
Heo, J.4
Iskandrian, A.E.5
-
25
-
-
79960757657
-
Electrophysiologic basis for the antiarrhythmic actions of ranolazine
-
21421082 10.1016/j.hrthm.2011.03.045
-
Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281-90.
-
(2011)
Heart Rhythm
, vol.8
, Issue.8
, pp. 1281-1290
-
-
Antzelevitch, C.1
Burashnikov, A.2
Sicouri, S.3
Belardinelli, L.4
-
26
-
-
31144473292
-
An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts
-
16234410 10.1124/jpet.105.094862 1:CAS:528:DC%2BD28XhtlWqtr8%3D
-
Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther. 2006;316(2):718-26.
-
(2006)
J Pharmacol Exp Ther
, vol.316
, Issue.2
, pp. 718-726
-
-
Wu, L.1
Shryock, J.C.2
Song, Y.3
Belardinelli, L.4
-
27
-
-
0344688172
-
Assessing predictors of drug-induced torsade de pointes
-
14654302 10.1016/j.tips.2003.10.002 1:CAS:528:DC%2BD3sXpsVSksL4%3D
-
Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24(12):619-25.
-
(2003)
Trends Pharmacol Sci
, vol.24
, Issue.12
, pp. 619-625
-
-
Belardinelli, L.1
Antzelevitch, C.2
Vos, M.A.3
-
28
-
-
0030032681
-
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
-
8616920 10.1161/01.CIR.93.1.135 1:CAS:528:DyaK28XhtVyhsrs%3D
-
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93(1):135-42.
-
(1996)
Circulation
, vol.93
, Issue.1
, pp. 135-142
-
-
McCormack, J.G.1
Barr, R.L.2
Wolff, A.A.3
Lopaschuk, G.D.4
-
29
-
-
0029996458
-
Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism
-
8729066 10.1006/jmcc.1996.0032 1:CAS:528:DyaK28Xht1emsLk%3D
-
Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol. 1996;28(2):341-50.
-
(1996)
J Mol Cell Cardiol
, vol.28
, Issue.2
, pp. 341-350
-
-
Clarke, B.1
Wyatt, K.M.2
McCormack, J.G.3
-
30
-
-
0141723313
-
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
-
12869391 10.1161/01.RES.0000086943.72932.71 1:CAS:528: DC%2BD3sXlvV2itLk%3D
-
MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2003;93(3):e26-32.
-
(2003)
Circ Res
, vol.93
, Issue.3
-
-
MacInnes, A.1
Fairman, D.A.2
Binding, P.3
Rhodes, J.4
Wyatt, M.J.5
Phelan, A.6
-
31
-
-
68049137918
-
Ranolazine improves endothelial function in patients with stable coronary artery disease
-
19444092 10.1097/MCA.0b013e32832a198b
-
Deshmukh SH, Patel SR, Pinassi E, Mindrescu C, Hermance EV, Infantino MN, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009;20(5):343-7.
-
(2009)
Coron Artery Dis
, vol.20
, Issue.5
, pp. 343-347
-
-
Deshmukh, S.H.1
Patel, S.R.2
Pinassi, E.3
Mindrescu, C.4
Hermance, E.V.5
Infantino, M.N.6
-
32
-
-
79958284578
-
Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs
-
21633249 10.1097/FJC.0b013e31821458e8 1:CAS:528:DC%2BC3MXntVeltbk%3D
-
Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, et al. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011;57(6):639-47.
-
(2011)
J Cardiovasc Pharmacol
, vol.57
, Issue.6
, pp. 639-647
-
-
Zhao, G.1
Walsh, E.2
Shryock, J.C.3
Messina, E.4
Wu, Y.5
Zeng, D.6
-
33
-
-
0035080560
-
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system
-
11330341 10.1007/s002100000378 1:CAS:528:DC%2BD3MXhslWmu7Y%3D
-
Letienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 2001;363(4):464-71.
-
(2001)
Naunyn Schmiedebergs Arch Pharmacol
, vol.363
, Issue.4
, pp. 464-471
-
-
Letienne, R.1
Vie, B.2
Puech, A.3
Vieu, S.4
Le Grand, B.5
John, G.W.6
-
34
-
-
0348129532
-
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial
-
14734593 10.1001/jama.291.3.309 1:CAS:528:DC%2BD2cXmtlansA%3D%3D
-
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309-16.
-
(2004)
JAMA
, vol.291
, Issue.3
, pp. 309-316
-
-
Chaitman, B.R.1
Pepine, C.J.2
Parker, J.O.3
Skopal, J.4
Chumakova, G.5
Kuch, J.6
-
35
-
-
34247526904
-
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial
-
17456819 10.1001/jama.297.16.1775 1:CAS:528:DC%2BD2sXkslaqsL0%3D
-
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775-83.
-
(2007)
JAMA
, vol.297
, Issue.16
, pp. 1775-1783
-
-
Morrow, D.A.1
Scirica, B.M.2
Karwatowska-Prokopczuk, E.3
Murphy, S.A.4
Budaj, A.5
Varshavsky, S.6
-
36
-
-
77956535593
-
The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease
-
20828645 10.1016/j.jacc.2010.04.042 1:CAS:528:DC%2BC3cXhtlWjt7jK
-
Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010;56(12):934-42.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.12
, pp. 934-942
-
-
Stone, P.H.1
Chaitman, B.R.2
Stocke, K.3
Sano, J.4
Devault, A.5
Koch, G.G.6
-
37
-
-
33646140572
-
Clinical pharmacokinetics of ranolazine
-
16640453 10.2165/00003088-200645050-00003 1:CAS:528:DC%2BD28Xlt1Kgsb8%3D
-
Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-91.
-
(2006)
Clin Pharmacokinet
, vol.45
, Issue.5
, pp. 469-491
-
-
Jerling, M.1
-
38
-
-
21044458297
-
Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets
-
15951470 10.1177/0091270005276739 1:CAS:528:DC%2BD2MXmsFymtLc%3D
-
Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol. 2005;45(7):802-9.
-
(2005)
J Clin Pharmacol
, vol.45
, Issue.7
, pp. 802-809
-
-
Abdallah, H.1
Jerling, M.2
-
39
-
-
24344483447
-
Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine
-
16153399 10.1016/j.clpt.2005.05.004 1:CAS:528:DC%2BD2MXpvV2rt70%3D
-
Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 2005;78(3):288-97.
-
(2005)
Clin Pharmacol Ther
, vol.78
, Issue.3
, pp. 288-297
-
-
Jerling, M.1
Abdallah, H.2
-
40
-
-
11144356285
-
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
-
15093870 10.1016/j.jacc.2003.11.045 1:CAS:528:DC%2BD2cXkt1Wksr4%3D
-
Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375-82.
-
(2004)
J Am Coll Cardiol
, vol.43
, Issue.8
, pp. 1375-1382
-
-
Chaitman, B.R.1
Skettino, S.L.2
Parker, J.O.3
Hanley, P.4
Meluzin, J.5
Kuch, J.6
-
41
-
-
33746192571
-
Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial
-
ERICA Investigators 16875985 10.1016/j.jacc.2006.05.044 1:CAS:528:DC%2BD28XntlWjsb0%3D
-
Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566-75.
-
(2006)
J Am Coll Cardiol
, vol.48
, Issue.3
, pp. 566-575
-
-
Stone, P.H.1
Gratsiansky, N.A.2
Blokhin, A.3
Huang, I.Z.4
Meng, L.5
-
42
-
-
33847385380
-
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE)
-
17349881 10.1016/j.jacc.2006.10.067 1:CAS:528:DC%2BD2sXivVams78%3D
-
Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49(10):1027-34.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.10
, pp. 1027-1034
-
-
Koren, M.J.1
Crager, M.R.2
Sweeney, M.3
-
43
-
-
0028016058
-
Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group
-
8044941 10.1161/01.CIR.90.2.726 1:STN:280:DyaK2czitVantA%3D%3D
-
Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994;90(2):726-34.
-
(1994)
Circulation
, vol.90
, Issue.2
, pp. 726-734
-
-
Thadani, U.1
Ezekowitz, M.2
Fenney, L.3
Chiang, Y.K.4
-
44
-
-
0002761812
-
Ranolazine: Antianginal therapy with a novel mechanism: Placebo controlled comparison versus atenolol (abstr.)
-
Rousseau M, Visser F, Bax J, Dubrey D, Cocco G, Pouleur H, et al. Ranolazine: antianginal therapy with a novel mechanism: placebo controlled comparison versus atenolol (abstr.). Eur Heart J. 1994;15(suppl I):95.
-
(1994)
Eur Heart J.
, vol.15
, Issue.SUPPL. I
, pp. 95
-
-
Rousseau, M.1
Visser, F.2
Bax, J.3
Dubrey, D.4
Cocco, G.5
Pouleur, H.6
-
45
-
-
0032983310
-
A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group
-
10404850 10.1016/S0002-9149(99)00190-3 1:CAS:528:DyaK1MXksFyltrw%3D
-
Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999;84(1):46-50.
-
(1999)
Am J Cardiol
, vol.84
, Issue.1
, pp. 46-50
-
-
Pepine, C.J.1
Wolff, A.A.2
-
46
-
-
12844280008
-
Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris
-
15670536 10.1016/j.amjcard.2004.09.025 1:CAS:528:DC%2BD2MXmvFynsw%3D%3D
-
Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311-6.
-
(2005)
Am J Cardiol
, vol.95
, Issue.3
, pp. 311-316
-
-
Rousseau, M.F.1
Pouleur, H.2
Cocco, G.3
Wolff, A.A.4
-
47
-
-
0027475036
-
Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to beta blockers in stable angina pectoris
-
8096670 10.1016/0002-9149(93)90901-N 1:STN:280:DyaK3s3itVKhtA%3D%3D
-
Siu SC, Jacoby RM, Phillips RT, Nesto RW. Comparative efficacy of nifedipine gastrointestinal therapeutic system versus diltiazem when added to beta blockers in stable angina pectoris. Am J Cardiol. 1993;71(11):887-92.
-
(1993)
Am J Cardiol
, vol.71
, Issue.11
, pp. 887-892
-
-
Siu, S.C.1
Jacoby, R.M.2
Phillips, R.T.3
Nesto, R.W.4
-
48
-
-
84855665797
-
Ranolazine for the treatment of refractory angina in a veterans population
-
Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, et al. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med. 2012;13(2):141.e1-141.e5.
-
(2012)
Cardiovasc Revasc Med.
, vol.13
, Issue.2
-
-
Greene, R.S.1
Rangel, R.M.2
Edwards, K.L.3
Chastain, L.M.4
Brouse, S.D.5
Alvarez, C.A.6
-
49
-
-
33845771723
-
Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials
-
17196454 10.1016/j.amjcard.2006.07.052 1:CAS:528:DC%2BD2sXhsFGruw%3D%3D
-
Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol. 2007;99(1):11-8.
-
(2007)
Am J Cardiol
, vol.99
, Issue.1
, pp. 11-18
-
-
Wenger, N.K.1
Chaitman, B.2
Vetrovec, G.W.3
-
50
-
-
79955937128
-
Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease
-
21565740 10.1016/j.jcmg.2011.03.007
-
Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514-22.
-
(2011)
JACC Cardiovasc Imaging
, vol.4
, Issue.5
, pp. 514-522
-
-
Mehta, P.K.1
Goykhman, P.2
Thomson, L.E.3
Shufelt, C.4
Wei, J.5
Yang, Y.6
-
51
-
-
84862577191
-
A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention
-
22709755 10.1016/j.ahj.2012.03.018 1:CAS:528:DC%2BC38Xntlyltbk%3D
-
Pelliccia F, Pasceri V, Marazzi G, Rosano G, Greco C, Gaudio C. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012;163(6):1019-23.
-
(2012)
Am Heart J
, vol.163
, Issue.6
, pp. 1019-1023
-
-
Pelliccia, F.1
Pasceri, V.2
Marazzi, G.3
Rosano, G.4
Greco, C.5
Gaudio, C.6
-
52
-
-
3342882854
-
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome
-
15031300 10.1124/jpet.104.066100 1:CAS:528:DC%2BD2cXmtVyksLY%3D
-
Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310(2):599-605.
-
(2004)
J Pharmacol Exp Ther
, vol.310
, Issue.2
, pp. 599-605
-
-
Wu, L.1
Shryock, J.C.2
Song, Y.3
Li, Y.4
Antzelevitch, C.5
Belardinelli, L.6
-
53
-
-
44249111216
-
Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy- 3-(2-methoxyphenoxy)propyl]-1-pipera zine (ranolazine) in anesthetized rabbits
-
18322148 10.1124/jpet.108.137729 1:CAS:528:DC%2BD1cXmsVOrt7w%3D
-
Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1- pipera zine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008;325(3):875-81.
-
(2008)
J Pharmacol Exp Ther
, vol.325
, Issue.3
, pp. 875-881
-
-
Wang, W.Q.1
Robertson, C.2
Dhalla, A.K.3
Belardinelli, L.4
-
54
-
-
78650845945
-
Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling
-
21059353 10.1016/j.yjmcc.2010.11.001 1:CAS:528:DC%2BC3MXjvFymsA%3D%3D
-
Zhao Z, Fefelova N, Shanmugam M, Bishara P, Babu GJ, Xie LH. Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling. J Mol Cell Cardiol. 2011;50(1):128-36.
-
(2011)
J Mol Cell Cardiol
, vol.50
, Issue.1
, pp. 128-136
-
-
Zhao, Z.1
Fefelova, N.2
Shanmugam, M.3
Bishara, P.4
Babu, G.J.5
Xie, L.H.6
-
55
-
-
79955006390
-
Reducing the late sodium current improves cardiac function during sodium pump inhibition by ouabain
-
21325441 10.1124/jpet.110.176776 1:CAS:528:DC%2BC3MXls1Kqur4%3D
-
Hoyer K, Song Y, Wang D, Phan D, Balschi J, Ingwall JS, et al. Reducing the late sodium current improves cardiac function during sodium pump inhibition by ouabain. J Pharmacol Exp Ther. 2011;337(2):513-23.
-
(2011)
J Pharmacol Exp Ther
, vol.337
, Issue.2
, pp. 513-523
-
-
Hoyer, K.1
Song, Y.2
Wang, D.3
Phan, D.4
Balschi, J.5
Ingwall, J.S.6
-
56
-
-
76449092876
-
Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model
-
20170820 10.1016/j.jacc.2009.10.033 1:CAS:528:DC%2BC3cXjvF2lur4%3D
-
Antoons G, Oros A, Beekman JD, Engelen MA, Houtman MJ, Belardinelli L, et al. Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010;55(8):801-9.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.8
, pp. 801-809
-
-
Antoons, G.1
Oros, A.2
Beekman, J.D.3
Engelen, M.A.4
Houtman, M.J.5
Belardinelli, L.6
-
57
-
-
70449090162
-
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion
-
19767532 10.1152/ajpheart.00173.2009 1:CAS:528:DC%2BD1MXhsValsbnI
-
Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923-9.
-
(2009)
Am J Physiol Heart Circ Physiol
, vol.297
, Issue.5
-
-
Dhalla, A.K.1
Wang, W.Q.2
Dow, J.3
Shryock, J.C.4
Belardinelli, L.5
Bhandari, A.6
-
58
-
-
78651326450
-
Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine
-
21232675 10.1016/j.jacc.2010.07.045 1:CAS:528:DC%2BC3MXit1eqs7s%3D
-
Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011;57(3):366-75.
-
(2011)
J Am Coll Cardiol
, vol.57
, Issue.3
, pp. 366-375
-
-
Morita, N.1
Lee, J.H.2
Xie, Y.3
Sovari, A.4
Qu, Z.5
Weiss, J.N.6
-
59
-
-
79952446402
-
Modelling the long QT syndrome with induced pluripotent stem cells
-
21240260 10.1038/nature09747 1:CAS:528:DC%2BC3MXmsFCqug%3D%3D
-
Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225-9.
-
(2011)
Nature
, vol.471
, Issue.7337
, pp. 225-229
-
-
Itzhaki, I.1
Maizels, L.2
Huber, I.3
Zwi-Dantsis, L.4
Caspi, O.5
Winterstern, A.6
-
60
-
-
35148850168
-
Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non st-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial
-
17804441 10.1161/CIRCULATIONAHA.107.724880 1:CAS:528:DC%2BD2sXhtFWru7rP
-
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non st-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-52.
-
(2007)
Circulation
, vol.116
, Issue.15
, pp. 1647-1652
-
-
Scirica, B.M.1
Morrow, D.A.2
Hod, H.3
Murphy, S.A.4
Belardinelli, L.5
Hedgepeth, C.M.6
-
61
-
-
77955422004
-
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: Observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial
-
20644019 10.1161/CIRCULATIONAHA.110.937136 1:CAS:528:DC%2BC3cXpslWnt7k%3D
-
Scirica BM, Braunwald E, Belardinelli L, Hedgepeth CM, Spinar J, Wang W, et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122(5):455-62.
-
(2010)
Circulation
, vol.122
, Issue.5
, pp. 455-462
-
-
Scirica, B.M.1
Braunwald, E.2
Belardinelli, L.3
Hedgepeth, C.M.4
Spinar, J.5
Wang, W.6
-
62
-
-
53049104215
-
Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome
-
18662191 10.1111/j.1540-8167.2008.01246.x
-
Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19(12):1289-93.
-
(2008)
J Cardiovasc Electrophysiol
, vol.19
, Issue.12
, pp. 1289-1293
-
-
Moss, A.J.1
Zareba, W.2
Schwarz, K.Q.3
Rosero, S.4
McNitt, S.5
Robinson, J.L.6
-
63
-
-
44349174320
-
Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: A case report
-
18507552 10.1111/j.1540-8159.2008.01083.x
-
Murdock DK, Kaliebe J, Overton N. Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol. 2008;31(6):765-8.
-
(2008)
Pacing Clin Electrophysiol
, vol.31
, Issue.6
, pp. 765-768
-
-
Murdock, D.K.1
Kaliebe, J.2
Overton, N.3
-
64
-
-
83555164819
-
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks
-
21895727 10.1111/j.1540-8159.2011.03208.x
-
Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34(12):1600-6.
-
(2011)
Pacing Clin Electrophysiol
, vol.34
, Issue.12
, pp. 1600-1606
-
-
Bunch, T.J.1
Mahapatra, S.2
Murdock, D.3
Molden, J.4
Weiss, J.P.5
May, H.T.6
-
65
-
-
55849135767
-
The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation
-
18679523
-
Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8(3):175-81.
-
(2008)
Indian Pacing Electrophysiol J
, vol.8
, Issue.3
, pp. 175-181
-
-
Murdock, D.K.1
Overton, N.2
Kersten, M.3
Kaliebe, J.4
Devecchi, F.5
-
66
-
-
73249135820
-
The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation
-
19763194
-
Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9(5):260-7.
-
(2009)
Indian Pacing Electrophysiol J
, vol.9
, Issue.5
, pp. 260-267
-
-
Murdock, D.K.1
Kersten, M.2
Kaliebe, J.3
Larrain, G.4
-
67
-
-
79960777504
-
The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: Implications for "pill in the pocket" approach in structural heart disease
-
Murdock DK, Reiffal JA, Kaliebe JW. The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for "pill in the pocket" approach in structural heart disease. J Am Coll Cardiol 2010;9:A6.E58.
-
(2010)
J Am Coll Cardiol
, vol.9
, Issue.A6
-
-
Murdock, D.K.1
Reiffal, J.A.2
Kaliebe, J.W.3
-
68
-
-
0027940144
-
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide
-
8059737 10.1016/0002-9149(94)90915-6 1:STN:280:DyaK2czjslOgtQ%3D%3D
-
Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 1994;74(5):503-5.
-
(1994)
Am J Cardiol
, vol.74
, Issue.5
, pp. 503-505
-
-
Capucci, A.1
Boriani, G.2
Botto, G.L.3
Lenzi, T.4
Rubino, I.5
Falcone, C.6
-
69
-
-
80051802104
-
Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting
-
21726841 10.1016/j.amjcard.2011.04.017 1:CAS:528:DC%2BC3MXhtVajtrbI
-
Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108(5):673-6.
-
(2011)
Am J Cardiol
, vol.108
, Issue.5
, pp. 673-676
-
-
Miles, R.H.1
Passman, R.2
Murdock, D.K.3
-
70
-
-
0035901250
-
Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): A randomised placebo-controlled trial
-
11265951 10.1016/S0140-6736(00)04196-9 1:CAS:528:DC%2BD3MXitVOitLs%3D
-
Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet. 2001;357(9259):830-6.
-
(2001)
Lancet
, vol.357
, Issue.9259
, pp. 830-836
-
-
Giri, S.1
White, C.M.2
Dunn, A.B.3
Felton, K.4
Freeman-Bosco, L.5
Reddy, P.6
-
71
-
-
77957571615
-
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation
-
20883928 10.1016/j.jacc.2010.08.600 1:CAS:528:DC%2BC3cXhsVagsL7N
-
Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56(15):1216-24.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.15
, pp. 1216-1224
-
-
Burashnikov, A.1
Sicouri, S.2
Di Diego, J.M.3
Belardinelli, L.4
Antzelevitch, C.5
-
72
-
-
77649299995
-
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria
-
19952329 10.1161/CIRCEP.109.886275 1:CAS:528:DC%2BC3cXjvFCmt7s%3D
-
Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol. 2010;3(1):88-95.
-
(2010)
Circ Arrhythm Electrophysiol
, vol.3
, Issue.1
, pp. 88-95
-
-
Sicouri, S.1
Burashnikov, A.2
Belardinelli, L.3
Antzelevitch, C.4
-
73
-
-
84864953997
-
Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation
-
22621799 10.1016/j.amjcard.2012.04.044 1:CAS:528:DC%2BC38Xntlyqs7s%3D
-
Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110(5):673-7.
-
(2012)
Am J Cardiol
, vol.110
, Issue.5
, pp. 673-677
-
-
Fragakis, N.1
Koskinas, K.C.2
Katritsis, D.G.3
Pagourelias, E.D.4
Zografos, T.5
Geleris, P.6
-
74
-
-
84857995406
-
The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: A case series
-
22229482 10.1111/j.1540-8159.2011.03298.x
-
Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35(3):302-7.
-
(2012)
Pacing Clin Electrophysiol
, vol.35
, Issue.3
, pp. 302-307
-
-
Murdock, D.K.1
Kaliebe, J.2
Larrain, G.3
-
75
-
-
33646007982
-
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current
-
16686675 10.1111/j.1540-8167.2006.00401.x
-
Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S169-77.
-
(2006)
J Cardiovasc Electrophysiol
, vol.17
, Issue.SUPPL. 1
-
-
Undrovinas, A.I.1
Belardinelli, L.2
Undrovinas, N.A.3
Sabbah, H.N.4
-
76
-
-
0031746154
-
Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: Comparison with dichloroacetate
-
9639058 10.1254/jjp.77.31 1:CAS:528:DyaK1cXjsFSktb4%3D
-
Matsumura H, Hara A, Hashizume H, Maruyama K, Abiko Y. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol. 1998;77(1):31-9.
-
(1998)
Jpn J Pharmacol
, vol.77
, Issue.1
, pp. 31-39
-
-
Matsumura, H.1
Hara, A.2
Hashizume, H.3
Maruyama, K.4
Abiko, Y.5
-
77
-
-
45549105581
-
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - Role of late sodium current and intracellular ion accumulation
-
18439620 10.1016/j.yjmcc.2008.03.006 1:CAS:528:DC%2BD1cXnvVOntL4%3D
-
Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45(1):32-43.
-
(2008)
J Mol Cell Cardiol
, vol.45
, Issue.1
, pp. 32-43
-
-
Sossalla, S.1
Wagner, S.2
Rasenack, E.C.3
Ruff, H.4
Weber, S.L.5
Schondube, F.A.6
-
78
-
-
67651067954
-
The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-l-carnitine to increase late INa and cause ventricular diastolic dysfunction
-
19403851 10.1124/jpet.109.151936 1:CAS:528:DC%2BD1MXpsFClsbo%3D
-
Wu Y, Song Y, Belardinelli L, Shryock JC. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-l-carnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther. 2009;330(2):550-7.
-
(2009)
J Pharmacol Exp Ther
, vol.330
, Issue.2
, pp. 550-557
-
-
Wu, Y.1
Song, Y.2
Belardinelli, L.3
Shryock, J.C.4
-
79
-
-
0028134824
-
Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease
-
7873471 10.1007/BF00877121 1:STN:280:DyaK2M7nvVCisg%3D%3D
-
Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8(5):741-7.
-
(1994)
Cardiovasc Drugs Ther
, vol.8
, Issue.5
, pp. 741-747
-
-
Hayashida, W.1
Van Eyll, C.2
Rousseau, M.F.3
Pouleur, H.4
-
80
-
-
33645381940
-
Left ventricular dyssynchrony in patients with heart failure: Pathophysiology, diagnosis and treatment
-
16568130 10.1038/ncpcardio0505
-
Bleeker GB, Bax JJ, Steendijk P, Schalij MJ, van der Wall EE. Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment. Nat Clin Pract Cardiovasc Med. 2006;3(4):213-9.
-
(2006)
Nat Clin Pract Cardiovasc Med
, vol.3
, Issue.4
, pp. 213-219
-
-
Bleeker, G.B.1
Bax, J.J.2
Steendijk, P.3
Schalij, M.J.4
Van Der Wall, E.E.5
-
81
-
-
7044274262
-
Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy
-
15519016 10.1016/j.jacc.2004.08.016
-
Bax JJ, Bleeker GB, Marwick TH, Molhoek SG, Boersma E, Steendijk P, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2004;44(9):1834-40.
-
(2004)
J Am Coll Cardiol
, vol.44
, Issue.9
, pp. 1834-1840
-
-
Bax, J.J.1
Bleeker, G.B.2
Marwick, T.H.3
Molhoek, S.G.4
Boersma, E.5
Steendijk, P.6
-
82
-
-
84868212488
-
Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease
-
Venkataraman R, Chen J, Garcia EV, Belardinelli L, Hage FG, Heo J, et al. Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. Am J Cardiol. 2012;110(10):1440-45.
-
(2012)
Am J Cardiol.
, vol.110
, Issue.10
, pp. 1440-1445
-
-
Venkataraman, R.1
Chen, J.2
Garcia, E.V.3
Belardinelli, L.4
Hage, F.G.5
Heo, J.6
-
83
-
-
79960430593
-
Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study
-
21538388 10.1002/clc.20897
-
Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol. 2011;34(7):426-32.
-
(2011)
Clin Cardiol
, vol.34
, Issue.7
, pp. 426-432
-
-
Jacobshagen, C.1
Belardinelli, L.2
Hasenfuss, G.3
Maier, L.S.4
-
84
-
-
84874063767
-
Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: Results from the RALI-DHF study
-
Maier L, Wachter R, Edelmann F, et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: results from the RALI-DHF study. J Am Coll Cardiol. 2012;59(13):E865-E865.
-
(2012)
J Am Coll Cardiol.
, vol.59
, Issue.13
-
-
Maier, L.1
Wachter, R.2
Edelmann, F.3
-
85
-
-
33747872227
-
Modification of myocardial substrate use as a therapy for heart failure
-
16932766 10.1038/ncpcardio0583 1:CAS:528:DC%2BD28XpvFegsbs%3D
-
Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med. 2006;3(9):490-8.
-
(2006)
Nat Clin Pract Cardiovasc Med
, vol.3
, Issue.9
, pp. 490-498
-
-
Abozguia, K.1
Clarke, K.2
Lee, L.3
Frenneaux, M.4
-
86
-
-
84857361073
-
Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle's cycle
-
Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl). 2012;90(1):31-43.
-
(2012)
J Mol Med (Berl).
, vol.90
, Issue.1
, pp. 31-43
-
-
Fang, Y.H.1
Piao, L.2
Hong, Z.3
Toth, P.T.4
Marsboom, G.5
Bache-Wiig, P.6
-
87
-
-
28944448286
-
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
-
16176940 10.1093/eurheartj/ehi495 1:CAS:528:DC%2BD28Xpt1Sjtg%3D%3D
-
Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42-8.
-
(2006)
Eur Heart J
, vol.27
, Issue.1
, pp. 42-48
-
-
Timmis, A.D.1
Chaitman, B.R.2
Crager, M.3
-
88
-
-
0035850403
-
Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials
-
11559268 10.1001/jama.286.10.1218 1:STN:280:DC%2BD3MrhvVegtw%3D%3D
-
Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218-27.
-
(2001)
JAMA
, vol.286
, Issue.10
, pp. 1218-1227
-
-
Boule, N.G.1
Haddad, E.2
Kenny, G.P.3
Wells, G.A.4
Sigal, R.J.5
-
89
-
-
65449149816
-
Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
-
19349325 10.1161/CIRCULATIONAHA.107.763912 1:CAS:528:DC%2BD1MXksVCku7o%3D
-
Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032-9.
-
(2009)
Circulation
, vol.119
, Issue.15
, pp. 2032-2039
-
-
Morrow, D.A.1
Scirica, B.M.2
Chaitman, B.R.3
McGuire, D.K.4
Murphy, S.A.5
Karwatowska-Prokopczuk, E.6
-
90
-
-
79953014923
-
Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice
-
21228065 10.1124/jpet.110.176396 1:CAS:528:DC%2BC3MXktVGqtb0%3D
-
Ning Y, Zhen W, Fu Z, Jiang J, Liu D, Belardinelli L, et al. Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1):50-8.
-
(2011)
J Pharmacol Exp Ther
, vol.337
, Issue.1
, pp. 50-58
-
-
Ning, Y.1
Zhen, W.2
Fu, Z.3
Jiang, J.4
Liu, D.5
Belardinelli, L.6
-
91
-
-
82955173063
-
Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model
-
21953372 10.1161/CIRCINTERVENTIONS.111.962852 1:CAS:528: DC%2BC3MXhs1ais73P
-
Nieminen T, Tavares CA, Pegler JR, Belardinelli L, Verrier RL. Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv. 2011;4(5):481-7.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, Issue.5
, pp. 481-487
-
-
Nieminen, T.1
Tavares, C.A.2
Pegler, J.R.3
Belardinelli, L.4
Verrier, R.L.5
|